Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband advances branding and IP for its AVERSA-based abuse-deterrent fentanyl patch, including planned FDA and international submissions.

Rhea-AI Summary

Nutriband (NTRB) received a USPTO Notice of Publication for commercial brand name trademarks for its lead abuse-deterrent fentanyl transdermal system, dated September 2, 2026.

The trademarks will appear in the USPTO Trademark Official Gazette, after which a 30‑day opposition period applies before a potential Notice of Allowance. Nutriband plans to secure full intellectual property rights for these commercial brand names in the United States and internationally and to submit the proposed brand name and product labeling to the FDA and other global regulators. The fentanyl patch uses AVERSA™ abuse‑deterrent technology and is projected to have potential peak annual US sales of $80 million to $200 million, supported by patents issued in 46 countries.

Positive

• USPTO Notice of Publication received for commercial brand name trademarks of lead fentanyl patch
• Product’s potential peak annual US sales estimated at $80–$200 million
• AVERSA™ abuse-deterrent technology protected by patents in 46 countries

Negative

• None.

Market Context

On Mar 30, 2026, Nutriband’s prior commercial-brand-name announcement was followed by a 2.02% 24-hou...

Analysis

On Mar 30, 2026, Nutriband’s prior commercial-brand-name announcement was followed by a 2.02% 24-hour gain; this USPTO publication advanced the same naming process from selection to opposition review.

Key Figures

USPTO notice date: September 2, 2026 Opposition period: 30 days Potential peak annual U.S. sales: $80 million to $200 million +1 more

USPTO notice date

September 2, 2026

Notice of Publication for commercial brand name trademarks

Opposition period

30 days

Before a potential Notice of Allowance

Potential peak annual U.S. sales

$80 million to $200 million

Abuse-deterrent fentanyl transdermal system

Patent coverage

46 countries

AVERSA abuse-deterrent technology

Historical Context

1 past event · Latest: Mar 30

1 event

1. Mar 30

   Commercial brand name

   24h Move

   +2.0%

   Selected a worldwide brand-name candidate and filed U.S. and international trademark protection.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

uspto, notice of publication, notice of allowance, opposition period, +1 more

5 terms

uspto regulatory

"United States Patent and Trademark Office (USPTO)"

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

notice of publication regulatory

"received a Notice of Publication from the United States Patent"

A notice of publication is a formal announcement that a required document — such as a regulatory filing, prospectus, circular, or official report — has been made publicly available by a company, regulator, or exchange. It matters to investors because it signals that new, official information is accessible and may start legal or procedural timelines (for example comment periods, rights exercises, or appeal windows), much like a posting on a community board that begins a set response period.

notice of allowance regulatory

"the USPTO is expected to issue a Notice of Allowance"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

opposition period regulatory

"during the 30-day opposition period"

A fixed legal window after a trademark application or public notice is published during which third parties can file a formal challenge to stop the mark from being registered. Think of it like a notice period that lets anyone who believes they own or will be harmed by the mark raise objections before it becomes official. For investors, outcomes of opposition proceedings can affect a company’s brand rights, licensing potential, and legal risks.

transdermal system medical

"an abuse deterrent fentanyl transdermal system"

A transdermal system is a medical product, most often a patch, that releases a drug through the skin into the bloodstream over a set period so patients receive steady doses without pills or injections; think of it as a slow‑release sticker that delivers medicine through the skin. For investors it matters because device design, manufacturing, regulatory approval, patent protection and patient convenience all shape market size, recurring revenue and the risk of recalls or legal issues.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system.

Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) dated September 2, 2026 for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed during the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance.

Nutriband intends to secure full intellectual property rights for its commercial brand names in the United States and internationally. The proposed brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval.

Nutriband’s fentanyl transdermal system is based on its AVERSA™ abuse deterrent transdermal technology and has the potential to be the world’s first abuse-deterrent patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl.

Nutriband’s abuse deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.¹ While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and the product is in development for all major medical markets worldwide.

Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
^{__________________________________________________________________________}

¹ Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband, Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc.

Brand Institute and Drug Safety Institute are registered trademarks of Brand Institute, Inc.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

FAQ

What is the next regulatory step after the USPTO Notice of Publication?

Trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed during the 30‑day opposition period, the USPTO is expected to issue a Notice of Allowance, which would enable Nutriband to move toward securing full intellectual property rights for its commercial brand names.

How does Nutriband plan to use the new commercial brand names?

The company plans to submit its proposed commercial worldwide brand name and product labeling for the abuse-deterrent fentanyl transdermal system to the FDA and other international regulatory agencies for review and approval.

What role does AVERSA™ technology play in Nutriband’s fentanyl patch?

AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into patches to help prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulants. The lead product is an abuse-deterrent fentanyl patch that uses this technology.